- Home
- PAY vs ACAD Comparison
PAY vs ACAD Comparison
Compare PAY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAY
- ACAD
- Stock Information
- Founded
- PAY 2004
- ACAD 1993
- Country
- PAY United States
- ACAD United States
- Employees
- PAY N/A
- ACAD N/A
- Industry
- PAY Computer Software: Prepackaged Software
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- PAY Technology
- ACAD Health Care
- Exchange
- PAY Nasdaq
- ACAD Nasdaq
- Market Cap
- PAY 4.0B
- ACAD 3.8B
- IPO Year
- PAY 2021
- ACAD 2004
- Fundamental
- Price
- PAY $28.69
- ACAD $20.98
- Analyst Decision
- PAY Hold
- ACAD Buy
- Analyst Count
- PAY 5
- ACAD 18
- Target Price
- PAY $36.40
- ACAD $27.71
- AVG Volume (30 Days)
- PAY 696.9K
- ACAD 2.0M
- Earning Date
- PAY 08-07-2025
- ACAD 08-05-2025
- Dividend Yield
- PAY N/A
- ACAD N/A
- EPS Growth
- PAY 74.18
- ACAD N/A
- EPS
- PAY 0.40
- ACAD 1.37
- Revenue
- PAY $962,105,000.00
- ACAD $996,283,000.00
- Revenue This Year
- PAY $27.22
- ACAD $13.39
- Revenue Next Year
- PAY $20.11
- ACAD $10.59
- P/E Ratio
- PAY $71.03
- ACAD $15.33
- Revenue Growth
- PAY 47.78
- ACAD 22.42
- 52 Week Low
- PAY $17.70
- ACAD $13.40
- 52 Week High
- PAY $40.43
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- PAY 26.57
- ACAD 45.70
- Support Level
- PAY $30.90
- ACAD $20.75
- Resistance Level
- PAY $31.67
- ACAD $23.09
- Average True Range (ATR)
- PAY 1.10
- ACAD 0.78
- MACD
- PAY -0.33
- ACAD -0.20
- Stochastic Oscillator
- PAY 0.71
- ACAD 9.83
About PAY Paymentus Holdings Inc.
Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers and financial institutions through a Software-as-a-Service, (SaaS), secure, omni-channel technology platform. The platform integrates into a biller's core financial and operating systems to provide flexible and secure access to payment processing of credit cards, debit cards, eChecks and digital wallets across a number of channels including online, mobile, IVR, call center, chatbot and voice-based assistants. The Company generates revenue from payment transaction fees processed through the Company's platform. The fees are generated as a percentage of transaction value or a specified fee per transaction.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.